Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00283309 · ClinicalTrials.gov registry record · Phase 4
Memantine or Riluzole Prophylaxis for Corticosteroid-induced Mood and Declarative Memory Changes
A Phase 4 study, sponsored by University of Texas Southwestern Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT00283309 is a Phase 4 study that was terminated before completion, run by University of Texas Southwestern Medical Center. The registered enrollment target is 20 participants.
The verdict
NCT00283309, a Phase 4 study, was terminated before completion, sponsored by University of Texas Southwestern Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
The primary purpose is to determine if patients scheduled to receive prescription corticosteroid therapy for inflammatory illnesses who are given either memantine or riluzole pretreatment will show lesser declarative memory impairment than those receiving placebo. The exploratory purpose is to determine if patients scheduled to receive prescription corticosteroid therapy for inflammatory illnesses who are given memantine or riluzole pretreatment will show a smaller increase in manic/hypomanic symptom severity than those receiving placebo.
Interventions
- DRUG Riluzole
- DRUG Memantine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2005-11 |
| Est. Completion | 2007-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00283309
The ClinicalTrials.gov registry entry for NCT00283309 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Riluzole is the first listed.
NCT00283309 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00283309 about?
NCT00283309 is a clinical study titled "Memantine or Riluzole Prophylaxis for Corticosteroid-induced Mood and Declarative Memory Changes". The primary purpose is to determine if patients scheduled to receive prescription corticosteroid therapy for inflammatory illnesses who are given either memantine or riluzole pretreatment will show lesser declarative memory impairment than those receiving placebo. The exploratory purpose is to dete...
What is the current status of trial NCT00283309?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2005-11. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00283309?
The interventions under investigation include: Riluzole (DRUG), Memantine (DRUG).
Who is sponsoring clinical trial NCT00283309?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.